- Home
- EXAS vs BOSC Comparison
EXAS vs BOSC Comparison
Compare EXAS & BOSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- BOSC
- Stock Information
- Founded
- EXAS 1995
- BOSC 1990
- Country
- EXAS United States
- BOSC Israel
- Employees
- EXAS N/A
- BOSC N/A
- Industry
- EXAS Medical Specialities
- BOSC Computer Communications Equipment
- Sector
- EXAS Health Care
- BOSC Telecommunications
- Exchange
- EXAS Nasdaq
- BOSC Nasdaq
- Market Cap
- EXAS 10.7B
- BOSC N/A
- IPO Year
- EXAS N/A
- BOSC 1996
- Fundamental
- Price
- EXAS $56.28
- BOSC $4.52
- Analyst Decision
- EXAS Strong Buy
- BOSC Strong Buy
- Analyst Count
- EXAS 20
- BOSC 1
- Target Price
- EXAS $70.68
- BOSC $5.00
- AVG Volume (30 Days)
- EXAS 3.6M
- BOSC 428.9K
- Earning Date
- EXAS 07-30-2025
- BOSC 05-29-2025
- Dividend Yield
- EXAS N/A
- BOSC N/A
- EPS Growth
- EXAS N/A
- BOSC 35.10
- EPS
- EXAS N/A
- BOSC 0.49
- Revenue
- EXAS $2,828,128,000.00
- BOSC $43,688,000.00
- Revenue This Year
- EXAS $14.58
- BOSC N/A
- Revenue Next Year
- EXAS $12.75
- BOSC N/A
- P/E Ratio
- EXAS N/A
- BOSC $9.29
- Revenue Growth
- EXAS 11.57
- BOSC 0.84
- 52 Week Low
- EXAS $39.97
- BOSC $2.50
- 52 Week High
- EXAS $72.83
- BOSC $5.50
- Technical
- Relative Strength Index (RSI)
- EXAS 61.48
- BOSC 70.17
- Support Level
- EXAS $55.26
- BOSC $3.83
- Resistance Level
- EXAS $58.68
- BOSC $5.50
- Average True Range (ATR)
- EXAS 1.98
- BOSC 0.26
- MACD
- EXAS -0.14
- BOSC 0.06
- Stochastic Oscillator
- EXAS 64.86
- BOSC 47.59
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.